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Abstract 
  Cyclin-dependent kinase inhibitors represented by the INK4 family comprising 
p16INK4A, p15INK4B, p18INK4C, and p19INK4D are regulators of the cell cycle shown to be 
aberrant in many types of cancer.  Mice lacking p18Ink4c exhibit a series of phenotypes 
including the development of widespread organomegaly and pituitary adenomas.  The 
objective of our study is to examine the role of p18INK4C in the pathogenesis of human 
pituitary tumors.  The protein and mRNA levels of p18INK4C were examined by 
immunohistochemistry and real-time reverse transcription-polymerase chain reaction, 
respectively.  The methylation status of the p18INK4C gene promoter and somatic 
mutations of the p18INK4C gene were also investigated.  p18INK4C protein expression was 
lost or significantly reduced in 64% of pituitary adenomas compared with levels in 
normal pituitary glands.  p18INK4C mRNA levels were low in all ACTH adenomas and 
non-functioning (NF)-FSH and in 42%, 70% and 66% of GH, PRL, and subtype 3 
adenomas, respectively.  p18INK4C mRNA levels were significantly associated with 
p18INK4C protein levels.  Neither methylated promoters in pituitary adenomas, except in 
1 NF-FSH adenoma, nor somatic mutations of the p18INK4C gene in any pituitary 
adenomas were detected.  The down-regulation of p18INK4C expression may contribute to 
the tumorigenesis of pituitary adenomas. 
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Introduction 
  Pituitary adenomas are common and potentially serious neoplasms that account for 
10-15% of all intracranial neoplasms [1].  Although pituitary adenomas arise as benign 
monoclonal neoplasms, alterations in classic oncogenes and tumor suppressor genes are 
rarely found in these tumors [2-8].  Recently, germline mutations in the aryl 
hydrocarbon receptor-interacting protein gene were identified in familial GH adenomas 
[9,10], whereas somatic mutations of the gene are rarely detected in sporadic GH 
adenomas [11].  In addition, over-expression of pituitary tumor transforming gene and a 
truncated form of fibroblast growth factor receptor-4 have been reported in pituitary 
adenomas [12,13].  Nevertheless, molecular mechanisms involved in the genesis of 
pituitary adenomas are scarcely known. 
  A critical point in the cell cycle is the G1/S transition checkpoint frequently aberrated 
in cancer cells.  Progression of the cell cycle is controlled by cyclins and 
cyclin-dependent kinase (CDK).  Cyclin/CDK complexes induce the progression of cells 
into the S phase by phosphorylating retinoblastoma protein (pRb) [14].  INK4 
comprising p16INK4A, p15INK4B, p18INK4C, and p19INK4D is a family of CDK inhibitors and 
binds specifically to CDK4 and CDK6, thereby preventing kinase activities [15].  
Therefore, inactivation of INK4 leads to activation of cyclin/CDK complexes, resulting in 
cell cycle progression.  
  Although expression of p16INK4A is frequently down-regulated in human pituitary 
adenomas [16-18], the role of other INK4 genes in pituitary tumor suppression has not yet 
been uncovered in human.  Mice lacking of p18Ink4c displayed organomegaly, 
intermediate-lobe pituitary tumors, lymphomas, testicular tumors, and 
pheochromocytomas [19].  p18Ink4c-/-; Pten+/- or p18Ink4c-/-; Men1+/- mice are reported to 
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develop anterior pituitary tumors with an accelerated rate compared to Pten+/- or Men1+/- 
mice, respectively [20,21].  Recently, van Veelen et al. reported that loss of p18Ink4c in 
combination with oncogenic Ret increases the risk of medullary thyroid carcinoma [22].  
These findings suggest that functional inactivation of the p18Ink4c gene is an important 
factor in murine endocrine tumors. 
  To define the role of p18INK4C in human pituitary tumorigenesis, we investigated 
protein and mRNA levels, promoter methylation status, and somatic mutations of the 
p18INK4C gene in pituitary adenomas. 
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Materials and methods 
Patients and tumor samples 
  Tumor samples were collected from unselected patients with sporadic pituitary 
adenomas.  Clinical information on the patients is described in Table 1.  In addition to 
the adenomas in Table 1, another 40 GH adenomas were used for investigating somatic 
mutations of p18INK4C.  Tumor size and invasiveness were defined on the basis of 
preoperative radiological investigations and operative findings and with a modified 
Hardy’s classification [23].  Grade I (microadenomas, <1 cm in diameter) and grade II 
(enclosed macroadenomas with or without suprasellar extension, ≥1 cm in diameter) 
tumors were defined as non-invasive.  Grade III (local invasion of sphenoid and/or 
cavernous sinus) and grade IV (diffusive invasion or destruction of sella) tumors were 
considered to be invasive.  All pituitary adenomas were obtained at the time of surgery 
at Toranomon Hospital (Tokyo, Japan).  The study was approved by our internal review 
board.  Fully informed consent was obtained in accordance with institutional guidelines.   
 
Immunohistochemical analysis 
  p18INK4C expression in 45 pituitary adenomas was investigated by 
immunohistochemical analysis.  To detect p18INK4C protein and Ki-67 antigen, 
immunolocalization experiments were carried out on sections from representative blocks 
of paraffin-embedded tissues using the labeled streptavidin-biotin method.  After 
deparaffinization and antigen retrieval using an autoclave oven technique, sections were 
incubated at 4 °C overnight with mouse monoclonal anti-p18 antibody (1:200; Santa Cruz 
Biotech, Santa Cruz, CA) or with mouse monoclonal anti-Ki-67 antibody (1:100; 
DakoCytomation, Glostrup, Denmark). Antigen-antibody complexes were detected using 
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the cobalt-3, 3’-diaminobenzidine reaction.  The slides were counter-stained lightly with 
hematoxylin or 1% methyl green and mounted for microscopic examination.  Sections of 
human colon carcinoma known to be positive for p18INK4C were used as positive controls.  
Sections incubated in phosphate-buffered saline without the primary antibody served as 
negative controls.  
  Each slide was examined by an observer blinded to the diagnosis and clinicopathologic 
data and further reviewed and confirmed by a second blinded observer.  Any intensity of 
nuclear staining was considered to present a positive stain for p18INK4C and Ki-67.  A 
total of 500 - 1000 cells were counted and the percentage of p18INK4C -stained tumor cells 
was scored on a scale of 0 to 4 (0, no staining; 1+, 1 - 5%; 2+, 5 - 30%; 3+, 30 - 50%; 4+, 
>50%).   The Ki-67 antigen labeling index was determined by counting the number of 
positive cells in a total of 500 - 1000 tumor cells observed in several representative 
high-power fields (x 400).  The results were expressed as a percentage of tumor cells 
with positive nuclei. 
 
p18INK4C mRNA expression analysis  
  p18INK4C mRNA levels in 49 pituitary adenomas were investigated.  Total RNA from 
pituitary adenomas was extracted using ISOGEN (Nippongene, Toyama, Japan) 
according to the manufacturer’s instructions.  cDNA was synthesized from total RNA 
using a Prime ScriptTM RT Reagent Kit (TaKaRa, Kyoto, Japan).  Quantitative real-time 
reverse transcription-polymerase chain reaction (RT-PCR) analysis was performed at 
least in duplicate using the Applied Biosystems 7300 Real Time PCR System (Applied 
Biosystems, Foster City, CA).  The nucleotide sequences of primers were for p18INK4C: 
forward, 5’-GGGGACCTAGAGCAACTTACT-3’ and reverse, 5’-GGCAATCTCGGG 
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ATTTCCAAG-3’; and for glyceraldehyde-3-phosphate dehydrogenase (GAPDH): 
forward, 5’-GAAGGTGAAGGTCGGAGTC-3’ and reverse, 5’-GAAGATGGTGATGG 
GATTTC-3’.  The final volume of 20 µl contained 10 µl of 2 x Power SYBR Green 
PCR Master Mix (Applied Biosystems) and each primer.  Genes were amplified with 
50oC for 2 min, 95oC for 10 min followed by 40 cycles of denaturation at 95oC for 15 sec, 
and annealing and extension at 60oC for 1 min.  GAPDH mRNA was simultaneously 
quantitated as an endogenous control and the p18INK4C gene expression in each sample 
was normalized to GAPDH expression.  
 
Bisulfite sequencing 
  Genomic DNA was extracted from pituitary adenomas using the Qiagen DNeasy 
Tissue Kit (Qiagen, Stanford, CA) according to manufacturer’s instruction.  The sodium 
bisulfite modification was performed with genomic DNA using MethylEasyTMXceed 
(Human Genetic Signatures, North Ryde, Australia) according to the manufacturer’s 
directions.  A primer pair for bisulfite sequencing (forward, 5’-TAGGAATTGGGGTAG 
TTGGGG-3’ and reverse, 5’-TTACCTCTCAAAAAAAATACCARTTT-3’) was 
designed to amplify a region of 425 bp containing 42 CpG dinucleotides.  
  PCR was carried out in a volume of 20 µl containing about 50 ng of bisulfite-treated 
genomic DNA using AmpliTaq Gold DNA polymerase (Applied Biosystems).  PCR 
samples were denatured at 95 °C for 10 min and then subjected to 45 cycles of 95 °C for 
30 sec, 50 °C for 30 sec, and 72 °C for 1 min.  The PCR products were subcloned into 
pT7Blue T-Vector (Novagen, Madison, WI) and 5 plasmid clones for each sample were 
sequenced. 
 
 8 
Analysis of somatic mutations 
  To investigate the possibility of inactivating mutations of the p18INK4C gene, genomic 
DNA from 89 adenomas was subjected to PCR amplification for the coding region in 
exons 2 and 3 of p18INK4C.  The nucleotide sequences of primers were, for exon 2 (PCR 
product size, 280 bp): forward, 5’-AGTCTCCGATGCCATCATGCAGC-3’ and reverse, 
5’-CACGTAGGCAACATTATTGACTTGTT-3’; and for exon 3 (PCR product size, 515 
bp): forward, 5’-GAAGGATTCTACCATTTCTACTTCTTT-3’ and reverse, 5’- 
CTGCTTAACATATGACAGAACTGT-3’. 
  PCR was carried out in a volume of 20 µl containing 50 ng of genomic DNA using 
TaKaRa Ex TaqTM (TaKaRa).  PCR samples were denatured at 94 °C for 5 min and then 
subjected to 35 cycles of 94 °C for 30 sec, 50 °C /exon 2 and 55 °C /exon 3 for 30 sec, 
and 72 °C for 1 min.  The PCR products were electrophoresed in a 1% agarose gel to 
confirm amplification.  After treatment of the products with ExoSAP-IT (USB 
Corporation, Cleveland, OH), samples were subjected to direct sequencing in sense and 
anti-sense directions using a Big Dye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems) and analyzed on an Applied Biosystems 3700 DNA Analyzer (Applied 
Biosystems). 
 
Statistical analyses 
  Using StatView J-4.5 software (Statview, Cary, NC), the Chi-square test and 
Mann-Whitney U test were performed to determine the significance of associations 
between different variables.  Significant differences were accepted at P < 0.05. 
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Results 
p18INK4C protein expression in human pituitary adenomas 
  We examined p18INK4C protein expression in 4 normal pituitary glands and 45 adenoma 
specimens.  In the 4 normal adenohypophyseal samples, p18INK4C protein exhibited 
nuclear reactivity with moderate or high density (30% - 60%; 3+ - 4+); no membrane or 
cytoplasmic localization was identified (Figures 1A and 1B).  p18INK4C protein 
expression was absent (Figure 1C), significantly low (p18INK4C protein expression scale of 
1+), and slightly low (p18INK4C protein scale of 2+) in 31%, 33%, and 29% of adenomas, 
respectively (Table 1).  Three tumors showed a normal or high level of p18INK4C protein 
(Figure 1D and Table 1).  The expression of p18INK4C protein in adenomas was not 
significantly related to patient age, gender, tumor size, or the Ki-67 labeling index (data 
not shown).  
 
p18INK4C mRNA levels in pituitary adenomas 
  To reveal the mechanisms responsible for the weak expression of p18INK4C protein, 
mRNA levels of p18INK4C were measured in the pituitary adenomas used for 
immunohistochemistry.  For comparison, p18INK4C mRNA levels in 3 normal pituitary 
glands were analyzed.  Expression levels that were less than 50% of the mean value for 
normal pituitary glands were classified arbitrarily as significantly low.  p18INK4C mRNA 
levels were significantly low in all ACTH adenomas and NF-FSH adenomas (Figure 2).  
p18INK4C mRNA levels were also significantly low in 42%, 70%, and 66% of GH, PRL, 
and subtype 3 adenomas, respectively (Figure 2).  A correlation between mRNA and 
protein levels of p18INK4C in 42 pituitary adenomas was observed (Table 2).   
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Methylation status of the p18INK4C gene promoter in pituitary adenomas 
  The methylation status of the promoter region of p18INK4C was determined by bisulfite 
genomic sequencing in adenomas with p18INK4C mRNA levels that were less than 30% of 
the value for normal pituitary glands.  Bisulfite sequencing revealed that CpG 
dinucleotides were methylated in 1 NF-FSH adenoma (sample number 5 in Table 1) (data 
not shown).  Whereas, all 42 CpG dinucleotides analyzed were unmethylated in normal 
pituitary glands and other adenomas (data not shown). 
 
Mutations of the p18INK4C gene in pituitary adenomas 
  Sequencing of genomic DNA from 89 pituitary adenomas of various types did not 
show any mutations within the coding region or splicing junctions of the p18INK4C gene.  
We detected a known single nucleotide polymorphism, c.342T>C (p.G114G) (rs1043141), 
in 5 GH adenomas and 1 NF-FSH adenoma. 
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Discussion 
  p18INK4C has been implicated as a tumor suppressor gene in a variety of cancers [24-28].  
In particular, loss of p18INK4C protein expression has been reported in various human 
tumors such as testicular cancers, Hodgkin lymphomas, hepatocellular carcinomas, 
medulloblastomas, and glioblastomas [24-28].  To clarify whether an attenuation of 
p18INK4C expression is involved in the development of human pituitary adenomas, we 
investigated the expression of p18INK4C at both the protein and mRNA levels.  p18INK4C 
protein expression was absent or significantly low in 64% tumors, consistent with a recent 
report of under-expression of p18INK4C in both hormonally active and inactive pituitary 
adenomas [29].  Although a correlation between the mRNA and protein levels of 
p18INK4C	 in most pituitary adenomas was observed, a few pituitary adenomas showed a 
discrepancy between mRNA and protein levels.  The mechanisms responsible for this 
discrepancy were not clear.  Furthermore, low p18INK4C mRNA levels in all NF-FSH 
adenomas and ACTH adenomas were observed, consistent with a report of significant 
under-expression of p18INK4C in ACTH adenomas [30].   Based on studies on knock-out 
mice [19-21], down-regulation of p18INK4C gene expression may be a cause of the 
tumorigenesis of pituitary adenomas rather than a consequence of adenoma development. 
  The promoter methylation status of the p18INK4C gene in pituitary adenomas with low 
mRNA levels was analyzed, because cytosine residues occurring in CpG dinucleotides 
are targets for DNA methylation, and gene expression is usually reduced when DNA 
methylation takes place at a promoter [31].  Hypermethylation was detected in only 1 
NF-FSH adenoma; the others showed no methylation in the promoter of the p18INK4C gene.  
Recently, Kirsch et al. reported that about 40% of pituitary adenomas displayed p18INK4C 
promoter methylation by the method of methylation-specific PCR (MSP) [29].  The 
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contrasting data on promoter methylation may be resulted from different methods.  
Although MSP is a simple, sensitive and less time consuming method [32], it is a 
qualitative method and can sometimes lead to false positive results unless the PCR 
conditions and primers have been designed with stringent criteria [33].  On the other 
hand, the bisulfite genomic sequencing is the most straightforward means of detecting 
methylation status, which denotes an accurate map of the position of each methylated 
cytosine residue [31,34].  Because putative binding sites of Sp1 and E2F in the promoter 
of the p18INK4C gene are critical for p18INK4C expression [35], we investigated a region of 
promoter containing binding sites of Sp1 and E2F.  Our results demonstrated that 
aberrant methylation was not a responsible factor for the low levels of p18INK4C in 
pituitary adenomas. 
Alternatively, the down-regulation of p18INK4C expression may be caused by other 
mechanisms.  For example, Tallack et al. reported that p18Ink4c expression was 
down-regulated in erythroid krüppel-like factor (EKLF)-null mice [36].  In addition, 
expression of p18Ink4c is down-regulated by activated RET or up-regulated by menin 
[37,38].  However, somatic mutations of MEN1 and RET are rare in human pituitary 
adenomas [5,6].  Therefore, EKLF or other unknown gene products may be responsible 
for the down-regulation of p18INK4C expression in human pituitary adenomas.  
  Furthermore, the mutational status of the p18INK4C gene was investigated in 89 pituitary 
adenomas.  However, no somatic mutations except for a known polymorphism were 
detected, consisting with the study by Kirsch et al. [29].  Genetic alterations of p18INK4C 
in other tumors as well as in cancer cell lines have also been reported to be rare or absent 
[39-41].  Therefore, our results suggest that somatic mutational inactivation of the 
p18INK4C gene does not contribute to the pathogenesis of pituitary tumors.   
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  We conclude that the down-regulation of p18INK4C expression may contribute to the 
development of pituitary adenomas. 
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Table 1  Clinical features of patients with pituitary adenomas and results of    
        immunohistochemistry for p18INK4C 
 
Sample 
number 
 Age Sex Pathological  
diagnosis 
Hardy’s 
classificationa 
p18INK4C 
immunohistochemistry b 
1 50 male NF-FSH IV-B 0 
2 43 male NF-FSH III-C 0 
3 71 male NF-FSH II-B 0 
4 59 male NF-FSH II-B 2+ 
5 35 male NF-FSH II-B 3+ 
6 40 male NF-FSH II-B 0 
7 67 male NF-FSH II-B 1+ 
8 41 male NF-FSH II-B 2+ 
9 78 male NF-FSH II-B 2+ 
10 68 male NF-FSH II-B 1+ 
11 42 male NF-FSH II-A 2+ 
12 46 female NF-FSH III-B 1+ 
13 71 female NF-FSH IV-B 1+ 
      
14 43 female silent ACTH IV-A 1+ 
15 57 female silent ACTH IV-0 2+ 
16 36 female silent ACTH III-B 1+ 
17 72 female silent ACTH III-C 2+ 
18 n.a. female ACTH IV-0 0 
19 29 female ACTH I-0 0 
20 55 female ACTH II-0 1+ 
21 45 female ACTH II-0 1+ 
      
22 23 male subtype 3 III-B 1+ 
23 47 female subtype 3 III-B 2+ 
24 20 female subtype 3 IV-C 1+ 
      
25 56 male PRL III-A 0 
26 45 male PRL III-0 0 
27 86 male PRL III-A not analyzed 
28 36 female PRL II-0 not analyzed 
29 39 female PRL III-0 not analyzed 
30 27 female PRL I-0 1+ 
31 41 female PRL II-A 2+ 
32 30 female PRL I-0 0 
33 20 female PRL III-B 1+ 
34 35 female PRL I-0 2+ 
 35* 28 female PRL II-A 2+ 
      
36 28 male TSH II-B 3+ 
37 46 male TSH II-B not analyzed 
      
38 25 female GH+PRL III-0 1+ 
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39 63 male GH  III-A 0 
40 48 male GH II-A 0 
41 55 male GH II-0 2+ 
42 26 male GH II-0 2+ 
43 61 male GH II-B not analyzed 
44 33 male GH III-B not analyzed 
 45* 56 male GH III-0 0 
 46* 33 male GH III-B 0 
47 39 female GH III-B not analyzed 
48 63 female GH II-A 4+ 
49 36 female GH II-0 2+ 
50 56 female GH II-0 0 
51 74 female GH II-0 1+ 
52 39 female GH I-0 1+ 
 
aTumor lesions are categorized based on the size of suprasellar expansion as grade A, 
expanded into the chiasmatic cistern but not up to the anterior third ventricle; B, reached 
the floor of the third ventricle; C, expanded into the third ventricle up to the foramen of 
Monroe; 0, no suprasellar expansion.  bThe percentage of p18INK4C-stained tumor cells 
was scored on a scale of 0 to 4 (0, no staining; 1+, 1 - 5%; 2+, 5 - 30%; 3+, 30 - 50%; 4+, 
> 50%), n.a., not available. *mRNA levels and somatic mutations of the p18INK4C gene 
were not analyzed.  
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Table 2  Correlation between p18INK4C mRNA and protein levels in pituitary   
        adenomas 
 
 
 No. of cases p18INK4C protein    
  −     ± +  
p18INK4C        42     (n = 27)     (n = 12)    (n = 3)       P 
mRNA levels* 
 
 < 50% 33        23         8          2        < 0.05  
 50 - 99%  6         2         4          0   
100% or over  3         2         0          1  
	 
*mean value for 3normal pituitary glands is considered as 100% 
	 
−, no or significantly low levels of p18INK4C protein expression (scales of 0 and 1+); ±, 
slightly low levels of p18INK4C protein (scale of 2+); +, normal levels of p18INK4C protein 
(scales of 3+ and 4+).  A Chi-square test was used for the statistical analysis and 
significant differences were accepted at P < 0.05. 
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Figure legends 
Figure 1: p18INK4C protein expression in pituitary adenomas.  (A) p18INK4C 
immunostaining in a normal pituitary gland showed a dense nuclear immunoreaction 
(scale of 3+).  Original magnification, x200.  (B) Higher magnification of the boxed 
area in (A) showing positive nuclear p18INK4C staining.  Original magnification, x400.  
(C) p18INK4C immunostaining in a pituitary adenoma (sample number 6) showed no 
immunoreaction (scale of 0). Original magnification, x100.  (D) p18INK4C 
immunostaining in a pituitary adenoma (sample number 48) showed a strong nuclear 
immunoreaction (scale of 4+).  Original magnification, x200.  
 
Figure 2:  p18INK4C mRNA levels in various types of pituitary adenomas 
  Graphs show mRNA levels of p18INK4C in pituitary adenomas (hatched bars) and 3 
normal pituitary glands (blank bars) determined by quantitative real-time RT-PCR.  The 
ratio of p18INK4C mRNA/GAPDH mRNA in each sample (at least duplicate) was 
calculated and the mean value was presented.  The samples were numbered according to 
the sample numbers in Table 1. 
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